Kevzara, an underperforming cure against serious coronavirus cases… This is the conclusion Sanofi laboratories got as announced in a press release, saying on Tuesday September 1, 2020 that they were ending the clinical trial on this medicine. The study, on phase 3, “has not reached its main nor its secondary assessment criteria comparatively with the placebo, and in both cases, in addition to usual hospital care” the pharmaceutical group said.
A treatment co-developed in 2017 by Sanofi and American laboratory Regeneron, first to fight against rheumatoid polyarthritis. The French laboratory conjectured that it could also have an effect on serious Covid-19 cases, and reduce lethality. The clinical trial was still on going a few days ago and including 420 patients from Argentina, Brazil, Chile, Canada, Israel, Italy, Germany, Japan, and even France and Russia.
Even though Kevzara (sarilumab) “did not deliver results we were hoping for, we are proud of the work accomplished by the team that has been entrusted with teaching us more on the potential use of Kevzara in the treatment of Covid-19” Sanofi said in the release, via John Reed, the company’s international head of research and development.
A pharmaceutical group also not planning “to continue other clinical studies on Kevzara as to cure Covid-19” the release reads. Anyway, research goes on since Sanofi is also working on a vaccine. It is said to be put on the market in 2021, if outcomes of the clinical trials are conclusive this time.